



# The TIMI Trials

## TIMI 14

**OBJECTIVE:** To evaluate the benefit of abciximab bolus plus 12 hour infusion alone or in conjunction with reduced dose thrombolytic therapy among patients presenting with ST elevation myocardial infarction.

1. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AJJ, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. **Abciximab facilitates the rate and extent of thrombolysis: Results of TIMI 14 trial.** *Circulation* 1999;99:2720-2732.
2. Antman EM, Gibson CM, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, Menown I, Mienaber CA, Rehders TC, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the TIMI 14 Investigators. **Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14.** *Eur Heart J* 2000; 21: 1944-53.
3. de Lemos JA, Antman EM, Giugliano RP, Coulter SA, McCabe CH, Lambrew C, Ghali M, Gibson CM. **Non-culprit blood flow is an independent correlate of ECG injury patterns after thrombolytic therapy: a TIMI 14 substudy.** *Circulation* 1998;98 (Suppl I):I-826.
4. Giugliano RP, Antman EM, McCabe CH, Anderson KM, Adgey AA, Kleiman NS, Ghali M, Van de Werf F, Braunwald E. **Abciximab + tPA improves coronary flow in a wide range of subgroups: results from TIMI 14.** *Circulation* 1998;98 (Suppl I):I-560.
5. Giugliano RP, Antman EM, McCabe CH, Menown IBA, Kleiman NS, Ghali M, Coussement PK, Braunwald E. **Factors associated with major hemorrhage during reperfusion therapy in acute myocardial infarction: A TIMI 14 substudy.** *J Am Coll Cardiol* 1999;33 (Suppl A):398A.
6. Verheugt FWA, Ohman EM, Antman EM. **Emergency room infusion of abciximab speeds up reperfusion in acute myocardial infarction eligible for primary PTCA.** *J Am Coll Cardiol* 1999;33 (Suppl A):354A.
7. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. **Determinants of coronary blood flow after thrombolytic administration.** TIMI Study Group. *Thrombolysis in Myocardial Infarction.* *J Am Coll Cardiol* 1999;34:1403-12.
8. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. **Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction.** The TIMI Study Group. *Thrombolysis in myocardial infarction.* *J Am Coll Cardiol* 1999;34:974-82.
9. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AAH, Gibson CM, Giugliano RP, Maschelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS, for the TIMI 14 Platelet Substudy Investigators. **High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.** *Circulation* 2000;101:2690-2695.
10. de Lemos JA, Antman EM, Giugliano RP, Morrow DA, McCabe CH, Charlesworth A, Schroeder R, Braunwald E. **Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram.** *Am Heart J* 2000; 140(3): 373-8.
11. de Lemos JA, Antman EM, Morrow DA, Llevadot J, Giugliano RP, Coulter SA, Schuhwerk KC, Arslanian S, McCabe CH, Gibson CM, Rifai N. **Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy.** *Clin Chim Acta* 2000;298:85-97.
12. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey M, Van der Wieken R, Van de Werf F, Braunwald E for the TIMI 14 Investigators. **Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial.** *Circulation* 2000; 101: 239-43.

13. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, Gibson CM, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Resolution of ST-segment elevation correlates with infarct related artery patency and flow after thrombolytic therapy. *Am J Cardiol* 2000; 85: 299-304.
14. Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CM. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (thrombolysis in myocardial infarction (TIMI) trials). *Am J Cardiol* 2000; 85:1409-1413.
15. Gibson CM, Murphy SA, Marble SJ, Schuhwerk K, de Lemos JA. Adjunctive stenting is associated with the development of Q-waves in acute MI patients: a TIMI 14 substudy. *Circulation* 2000; 102(Suppl II): II-434.
16. Cooper HA, de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM. Single-lead ST-segment resolution to predict epicardial flow following fibrinolytic therapy: a useful bedside tool in acute myocardial infarction. *Circulation* 2001;104 (Suppl II):II-785.
17. Cooper HA, de Lemos JA, Murphy SA, McCabe CH, Schuhwerk KC, Antman EM, Braunwald E. Relation between time-to-pharmacologic reperfusion and the probability of achieving complete ST-segment resolution in ST elevation myocardial infarction. *J Am Coll Cardiol* 2001; 37 (Suppl.A): 339A.
18. Gibson CM, Murphy SA, Kraimer N, Pai R, Weisberg S, Marble SJ, Angeja BG, de Lemos J, Hollander JE, Weber J. Cocaine induced myocardial infarction is associated with reduced microvascular perfusion. *Circulation* 2001;104 (Suppl II):II-728.
19. Sutsch G, Gibson CM, Murphy SA, Amann FW. The impact of embolization protection on angiographic parameters in PCI with stenting in AMI. *Eur Heart J* 2001;22 (Abstr suppl):119.
20. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald E. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. *Am J Cardiol* 2001;88:353-8.
21. de Lemos JA, Gibson CM, Antman EM, Murphy SA, Morrow DA, Schuhwerk KC, Schweiger M, Coussement P, Van de Werf F, Braunwald E. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial. *Am Heart J* 2001;141:592-8.
22. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. *Circulation* 2001;103:2550-4.
23. Gibson CM, Kirtane AJ, Murphy SA, Marble SJ, de Lemos JA, Antman EM, Braunwald E. Impact of contrast agent type (ionic versus nonionic) used for coronary angiography on angiographic, electrocardiographic, and clinical outcomes following thrombolytic administration in acute myocardial infarction. *Catheter Cardiovasc Interv* 2001;53:6-11.
24. Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. *Am J Cardiol* 2001;87:450-3,A6.
25. Giri S, Gibson CM, Eisenhauer A, Kuntz R, Rogers C, Murphy S, Mitchel J, Antman EM, Simon DI. Aging of intracoronary thrombus due to delayed time-to-reperfusion increases ischemic and angiographic complications in acute myocardial infarction. *J Am Coll Cardiol* 2002;39 (Suppl A):281A.
26. Marks DS, Gudapati SB, Kleczka JF, Murphy S, Cannon CP, Braunwald E. Electrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarction. *J Am Coll Cardiol* 2002;39 (Suppl A):331A.
27. Murphy SA, Giugliano RP, Wong GC, Cannon CP, Antman EM, Gibson CM. Comparison of the frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A TIMI 14 and TIMI 9 substudy. *J Am Coll Cardiol* 2002;39 (Suppl A):279A.
28. Angeja BG, de Lemos J, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson CM. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. *Am Heart J* 2002;144:649-56.
29. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E, Gibson CM. The Smoker's Paradox: Insights from the Angiographic Substudies of the TIMI Trials. *J Thromb Thrombolysis* 2002;13:133-9.

30. Antman EM, Cooper HA, Gibson CM, de Lemos JA, McCabe CH, Giugliano RP, Coussement P, Murphy S, Scherer J, Anderson K, Van de Werf, and Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction: Insights from TIMI 14 and InTIME II. *Eur Heart J* 2002; 23:928-33.
31. Cooper HA, deLemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM, Braunwald E. Minimal ST-segment deviation: A simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. *Am Heart J* 2002;144:790-795.
32. Antman EM, Cooper HA, Gibson CM, de Lemos JA, McCabe CH, Giugliano RP, Coussement P, Murphy S, Scherer J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction: Insights from TIMI 14 and InTIME-II. *Eur Heart J* 2002;23:928-933.
33. Murphy SA, Dauterman K, de Lemos JA, Kermgard S, Antman EM, Braunwald E, and Gibson CM for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave MI in the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. *Am Heart J* 2003;146:42-47.
34. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. *Circulation* 2004;109:186-190.